These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9391700)

  • 21. Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process.
    Park JH; Yan YD; Chi SC; Hwang DH; Shanmugam S; Lyoo WS; Woo JS; Yong CS; Choi HG
    J Pharm Pharmacol; 2011 Apr; 63(4):491-9. PubMed ID: 21401600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suspected anaphylactic reaction to Cremophor EL.
    Dye D; Watkins J
    Br Med J; 1980 Jun; 280(6228):1353. PubMed ID: 7388538
    [No Abstract]   [Full Text] [Related]  

  • 24. Taxol(®)-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor(®) EL.
    Vader P; Fens MH; Sachini N; van Oirschot BA; Andringa G; Egberts AC; Gaillard CA; Rasmussen JT; van Wijk R; van Solinge WW; Schiffelers RM
    Nanomedicine (Lond); 2013 Jul; 8(7):1127-35. PubMed ID: 23384701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporin A and Cremophor-EL augment renal vascular responses to various agonists and nerve stimulation.
    Yariş E; Tuncer M
    Arch Int Pharmacodyn Ther; 1995; 329(3):405-17. PubMed ID: 8546539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel-induced nail changes: possible role of its vehicle (Cremophor EL).
    Minutilli E; Izzo F; Natoli G; Psaila A; Di Filippo F; Terzoli E
    Eur J Dermatol; 2006; 16(6):693-4. PubMed ID: 17229616
    [No Abstract]   [Full Text] [Related]  

  • 27. Cremophor EL augments the cytotoxicity of hydrogen peroxide in lymphocytes dissociated from rat thymus glands.
    Iwase K; Oyama Y; Tatsuishi T; Yamaguchi JY; Nishimura Y; Kanada A; Kobayashi M; Maemura Y; Ishida S; Okano Y
    Toxicol Lett; 2004 Dec; 154(1-2):143-8. PubMed ID: 15475188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The removal of Cremophor EL from paclitaxel for quantitative analysis by HPLC-UV.
    Perdue JD; Seaton PJ; Tyrell JA; DeVido DR
    J Pharm Biomed Anal; 2006 Apr; 41(1):117-23. PubMed ID: 16324815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal.
    Kessel D; Woodburn K; Decker D; Sykes E
    Oncol Res; 1995; 7(5):207-12. PubMed ID: 8534926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
    Nuijen B; Bouma M; Manada C; Jimeno JM; Bult A; Beijnen JH
    PDA J Pharm Sci Technol; 2001; 55(4):223-9. PubMed ID: 11505554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects.
    Tomaru A; Takeda-Morishita M; Maeda K; Banba H; Takayama K; Kumagai Y; Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2015 Jun; 30(3):221-6. PubMed ID: 25882073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL; Kossoff E
    Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct vascular smooth muscle contractile effect of cyclosporin A and its vehicle in rabbit isolated arteries.
    Yariş E; Tuncer M; Kayaalp SO; Ilhan M
    Arch Int Pharmacodyn Ther; 1994; 327(2):166-74. PubMed ID: 7979825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
    Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cremophor EL-based nanoemulsion enhances transcellular permeation of emodin through glucuronidation reduction in UGT1A1-overexpressing MDCKII cells.
    Zhang T; Dong D; Lu D; Wang S; Wu B
    Int J Pharm; 2016 Mar; 501(1-2):190-8. PubMed ID: 26850314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cremophor EL test for identification of Malassezia species].
    Zhang RF; Ran YP; Dai YL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 41(4):692-5. PubMed ID: 20848798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations.
    Tsallas A; Jackson J; Burt H
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):431-44. PubMed ID: 21069339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
    Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
    Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of unpurified Cremophor EL on the solution stability of paclitaxel.
    Gogate US; Schwartz PA; Agharkar SN
    Pharm Dev Technol; 2009; 14(1):1-8. PubMed ID: 18791935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cremophor EL, a non-ionic surfactant, promotes Ca(2+)-dependent process of cell death in rat thymocytes.
    Yamaguchi JY; Nishimura Y; Kanada A; Kobayashi M; Mishima K; Tatsuishi T; Iwase K; Oyama Y
    Toxicology; 2005 Aug; 211(3):179-86. PubMed ID: 15925021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.